Refractory Acute Myeloid Leukemia Clinical Trials in Atlanta, Georgia

3 studies are recruiting for refractory acute myeloid leukemia in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

    This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) who have undergone allogenic…

    Stage
    Phase 1
    Ages
    Up to 21
    Site
    Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia
    Locations
    12 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT07012044 on ClinicalTrials.gov

  2. Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

    This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that did not go into remission after …

    Stage
    Phase 1
    Ages
    1 to 30
    Site
    Children's Healthcare of Atlanta, Atlanta, Georgia
    Locations
    10 in total
    Run by
    St. Jude Children's Research Hospital

    See if you can join NCT06177067 on ClinicalTrials.gov

  3. Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

    This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
    Locations
    22 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT06484062 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.